Best Peptides for Fat Loss

Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.

Phase 2 data shows potential best-in-class efficacy with ~24% weight loss

Ipamorelin is a selective growth hormone secretagogue that stimulates the release of growth hormone from the pituitary gland without significantly affecting cortisol or prolactin.

GH-mediated fat metabolism improvement

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.

FDA-approved for visceral fat reduction, strong clinical evidence

Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials.

Clinical trials show up to 22.5% body weight loss, superior to semaglutide

Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. Its larger molecular size from fusion with an Fc fragment extends half-life and may reduce some GI side effects.

Provides moderate weight loss alongside glycemic control

Human Growth Hormone (somatropin) is a 191-amino acid protein identical to naturally produced GH. FDA-approved for growth hormone deficiency, Turner syndrome, and other conditions. Widely used off-label for anti-aging and performance.

Increases lipolysis and metabolic rate

Setmelanotide (Imcivree) is an FDA-approved MC4R agonist for chronic weight management in patients with obesity due to specific genetic conditions (POMC, PCSK1, or LEPR deficiency).

FDA-approved for rare genetic obesity with dramatic efficacy in target population

AOD-9604 is a modified fragment of human growth hormone (HGH fragment 176-191). It was developed to have the fat-reducing effects of growth hormone without the adverse effects on blood sugar or growth.

Designed specifically for fat reduction without GH side effects

A targeted fat loss stack combining AOD-9604 (the fat-burning fragment of HGH) with CJC-1295 and Ipamorelin for comprehensive body recomposition. This blend addresses fat loss directly while supporting lean mass through GH optimization.

Primary use - targeted fat reduction

Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.

Phase 3 trials show CagriSema achieves greater weight loss than semaglutide alone

Exenatide was the first GLP-1 receptor agonist approved in the US, derived from a compound found in Gila monster saliva. Available as Byetta (twice daily) and Bydureon (once weekly extended-release).

Promotes weight loss through appetite suppression and delayed gastric emptying

HGH Fragment 176-191 is the fat-reducing portion of the growth hormone molecule. Unlike AOD-9604 (which has an additional tyrosine), this is the exact fragment of HGH responsible for lipolytic effects.

Isolated fat-burning fragment of growth hormone

Liraglutide is a GLP-1 receptor agonist FDA-approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was one of the first daily GLP-1 agonists and paved the way for newer weekly options like semaglutide.

FDA-approved for chronic weight management with ~8% average weight loss

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone.

GH promotes lipolysis and fat oxidation

Semaglutide is a GLP-1 receptor agonist that has revolutionized weight management and diabetes treatment. FDA-approved as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral form), it has become one of the most prescribed peptides worldwide.

FDA-approved for chronic weight management with proven efficacy of 15-20% body weight loss

Growth Hormone Releasing Peptide 2 (GHRP-2) is considered one of the most potent GHRPs available. It provides strong GH release with moderate hunger increase compared to GHRP-6.

GH promotes lipolysis and fat oxidation

Sermorelin is a synthetic analog of GHRH consisting of the first 29 amino acids of the natural hormone. It was previously FDA-approved for GH deficiency diagnosis and treatment in children.

GH-mediated metabolic benefits

SHLP2 (Small Humanin-Like Peptide 2) is a mitochondrial-derived peptide similar to humanin. It has shown insulin-sensitizing and cytoprotective effects in research, with potential metabolic benefits.

Insulin-sensitizing effects may support metabolic health

Pramlintide (Symlin) is a synthetic analog of amylin, FDA-approved as an adjunct to insulin therapy in type 1 and type 2 diabetes. It helps control post-meal blood sugar spikes and promotes modest weight loss.

FDA-approved diabetes drug with modest weight loss benefit

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a mitochondrial-derived peptide that plays a key role in metabolic regulation and has emerged as a significant longevity research target.

Enhances glucose uptake and metabolic function

Melanotan II is a synthetic peptide analog of α-MSH with broader receptor activity than Melanotan I. It produces tanning effects and has notable effects on sexual function and appetite suppression.

Appetite suppression through MC4R, though not primary use

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with extended half-life and enhanced potency. The modifications prevent binding to IGF binding proteins, increasing bioavailability.

Enhances fat metabolism through IGF-1 pathway

The most popular growth hormone secretagogue combination. CJC-1295 (a GHRH analog) and Ipamorelin (a ghrelin mimetic) work synergistically to stimulate natural growth hormone release with potentially greater effects than either peptide alone.

GH promotes lipolysis and body recomposition

A powerful tri-blend combining Sermorelin (a GHRH analog) with two growth hormone releasing peptides. This combination produces significantly greater GH release than any single peptide, with studies showing up to 54-fold increases in pulsatile GH secretion.

GH-mediated fat metabolism

Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.

GH promotes lipolysis and fat oxidation

MK-677, also known as Ibutamoren, is an orally active growth hormone secretagogue. Unlike peptides, it can be taken orally and has a long half-life, providing 24-hour GH elevation.

GH elevation promotes fat oxidation despite appetite increase